Onconomics looks at which chemotherapy works best, and which is ineffective for cancer. It offers a detailed, easy-to-use results summary on the effectiveness of a given chemotherapy agent. Its goal is to help the clinician select the most potent chemotherapy or combination of chemotherapies for a given situation. Knowing that not all tumors behave the same way.
Being a drug efficacy test, this test analyzes the effectiveness of various chemotherapeutic agents on your specific cancer cells, creating a personalized profile to guide treatment.
The test measures the CTC count in the blood.
This information will help clinicians and patients understand the progression of cancer and treatment response.
Assessing the genetic expressions of cancer reveals the resistance and sensitivity of cancer cells.
With this knowledge, treatment plans can be personalized to maximize effectiveness and minimize side effects.
For example, the treatment protocols can be rotated on a shorter timeline so that it benefits before the cells become resistant.
Chemotherapy can be exhausting. It takes a toll on the patient, and if the chemo doesn’t work, it is even more devastating.
To find out whether the chemotherapeutic agent will work for a specific cancer of the patient, an Onconomics test is used.
Onconomics tests over 50 chemotherapeutic substances and 60+ targeted drugs, helping to identify the most suitable treatments for each patient.
Reserve your 30-minute free consultation
Onconomics assesses the genome profile using a dual approach to evaluate specific cancer treatments and drugs.
It offers an in-depth breakdown of the most suitable and successful treatment options for cancer.
It serves as a guide to the treating physician as to the most effective chemotherapy vs a standard protocol which may not work as well. This is particularly important when 2-3rd line treatments are used and found ineffective.
It provides the insights to hit the cancer when it has mutated beyond current standard protocols; whereby it becomes a guessing game.
Oncotrail has undergone rigorous evaluation to ensure high sensitivity and specificity, making it an invaluable tool for diagnostic purposes.
Through high-precision techniques, the test is used to monitor the effectiveness of a particular cancer treatment. This would objectively provide information on how well the treatment is going.
The non-invasive tracking of the cancer status would notify a treating physician whether to adjust current management or stay the course. This would be important to know in almost real-time rather than to find out much later that a treatment doesn't apply to a particular person.
Whole peripheral blood sample
15-25ml blood, minimum 400mg tissue
10-12 days in the lab
21 days after sample collection
Applicable for all cancer types
To whom it is relevant:
A patient-centric revolution in cancer testing and monitoring. We are devoted to providing personalized tests designed with each patient’s unique genetic profile in mind.
©2024 All Rights Reserved. Designed by Bee High Media.
